A research group supported by the organization "Arc Institute" has presented a new model of artificial intelligence that combines the genomes of various living species, aimed at developing new drugs. The "Ivo 2" model contains over 128 thousand complete genomes in its database, hosted on "Amazon Web Services", a subsidiary of "Amazon", specializing in cloud computing. Collaboration with the giant graphics card manufacturer "NVIDIA" enabled the development of this model, which was created using around 2000 H100 chips, the flagship product of "NVIDIA".
"The goal of this partnership with the 'Ivo 2' model is to create a tool capable of 'accelerating understanding of complex human diseases'," noted Silvana Connerman, director of the "Arc Institute", coordinating and financing scientific projects. It is expected that the model will enable 'understanding genetic variations associated with a specific disease', and then 'creating new molecules specifically targeting these areas for the treatment of diseases'," said the statement from "NVIDIA".
Tests conducted using the 'Ivo 2' model on genomes associated with breast cancer allowed for a high accuracy of 90% in identifying deleterious or benign genetic mutations, according to the "Arc Institute".
